The non-pharmacologic nasal mist uses hydroxypropyl methylcellulose to form a protective physical barrier in the nasal passages, trapping and blocking airborne allergens.

Nearly 1 in 4 patients treated with lecanemab for mild cognitive impairment or mild Alzheimer disease (AD) with confirmed amyloid pathology develop amyloid-rela ...

Lerochol autoinjector is expected to launch by January 2027. The Food and Drug Administration (FDA) has approved a new once-monthly autoinjector presentation of Lerochol ® (lerodalcibep-liga), a third ...

The phase 3 ALKIVIA study met its primary endpoint, demonstrating significant and sustained improvements in disease activity and muscle strength for patients with active autoimmune myositis.

Many people with atypical Alzheimer disease (AD) do not meet eligibility criteria for anti-amyloid therapies (AAT), according to a study published online August 5 in Neurology. Dror Shir, MD, from the ...

States are moving faster and further than federal regulators to get kratom off store shelves, with some banning the herb outright while a pending federal rule targets only one of its chemicals.

Trastuzumab deruxtecan (Enhertu) significantly improved PFS compared with standard of care as a first-line treatment for HER2-mutant nonsquamous NSCLC. Topline results were announced from the phase 3 ...

In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic ...

The device enables eligible adult wheelchair users living with spinal cord injury to walk and perform some activities of daily living.

Adding iberdomide to daratumumab and dexamethasone significantly increased the MRD-negative complete response rate to 41% vs 21% with DVd in patients with RRMM. The Food and Drug Administration (FDA) ...

MHT use linked to significantly lower odds of clinical dementia diagnoses and symptoms of memory/functional decline ...